Teng Li
李腾
Teng Li is the co-founder and president of Bluepha (蓝晶微生物), a Chinese synthetic biology company. He holds a PhD in biomaterials and synthetic biology from Tsinghua University, where he also completed his undergraduate studies in life sciences . Li co-founded Bluepha alongside fellow Tsinghua PhD Zhang Haoqian, with the pair described as among the earliest young scholars in China to pursue synthetic biology research . The company, which has been covered in FreeS Fund materials dating back to 2019, focuses on green innovation opportunities in synthetic biology .
AI-generated — may contain errors, please verify.
Coverage
The U.S.-China Biotech Race: Where Are the Opportunities in Synthetic Biology? | FreeS Fund Dialogue
Over the next five to ten years, which technologies will have a significant impact on synthetic biology?
[Live Tomorrow] In Conversation with Bluepha | Synthetic Biology: From Groping in the Dark to Riding the Wave
Going live tomorrow at 10 a.m. sharp.
Untangling the Ins and Outs of Carbon Emissions to Find the Path to Carbon Neutrality | FreeS Research Institute
What Investment Opportunities Exist in the Hundred-Trillion-Yuan Carbon Neutrality Market?
How Should We Think About Green Investing? | FreeS Research Institute
Why Does Carbon Neutrality Have to Be Zero?
Synthetic Biology: The *Heavenly Crafts* of the Next Twenty Years | 2021 FreeS Fund Annual Investor Summit
How will the convergence of biotechnology and data science transform the production methods for over 60% of the world's physical goods?
How to Break Through Innovation with the Power of Interdisciplinary Collaboration? | FreeS Fund Biomedical and Pharmaceutical Investment Summit Transcript
What should you do if you discover a mismatch between technology and market?
Blue Ocean Strategy: How Early-Stage Biopharma Startups Can Break Through and Win with Big Pharma | FreeS Fund 2020 Biopharma Summit Session 3 — Registration Open
From "Me Worse" to "First in Class": How Can Biopharma Companies Compete Through Differentiation?
Bluepha Closes RMB 40 Million Series A Round | FreeS Fund Deal Brief
Leading Global Engineered Microbe Development
Beauty Brands Entering China, Becoming India's Third-Largest E-Commerce Player, and Betting on Biomedical — 22 Developments and 5 Takeaways | FreeS Fund Bulletin · September
Do what's right, not what's easy.
Bluepha Completes Pre-A Round, Angel Investor FreeS Fund Continues to Follow On | FreeS Fund Investment News
Create more microbes to fully satisfy people's pursuit of a better life.
![[Live Tomorrow] In Conversation with Bluepha | Synthetic Biology: From Groping in the Dark to Riding the Wave](/_next/image?url=https%3A%2F%2Fkkcktdhgzddmdjdjoenc.supabase.co%2Fstorage%2Fv1%2Fobject%2Fpublic%2Fmedia%2Fimages%2F45f83c6a-7c35-4040-ba2d-210c7948ac95%2Fd7061a92cbcc.jpg&w=384&q=75)
